Amgen's Q2 earnings call reveals solid revenue and EPS growth driven by established products like Enbrel and denosumab. The company raises its 2012 guidance based on strong H1 performance. However, uncertainties aroundå®‰ never products and increased R&D investments for new pipeline candidates create short-term concerns. The stock is likely to experience a marginal dip in the coming weeks. [-1]